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Special Report

Proton therapy for adults with mediastinal lymphomas:
the International Lymphoma Radiation Oncology
Group guidelines
Bouthaina Shbib Dabaja,1 Bradford S. Hoppe,2 John P. Plastaras,3 Wayne Newhauser,4 Katerina Rosolova,5,6 Stella Flampouri,2
Radhe Mohan,7 N. George Mikhaeel,8 Youlia Kirova,9 Lena Specht,10 and Joachim Yahalom11

Among adult lymphoma survivors, radiation treatment techniques that increase the excess radiation dose to organs at
risk (OARs) put patients at risk for increased side effects,
especially late toxicities. Minimizing radiation to OARs in
adults patients with Hodgkin and non-Hodgkin lymphomas
involving the mediastinum is the deciding factor for the
choice of treatment modality. Proton therapy may help to
reduce the radiation dose to the OARs and reduce toxicities,

especially the risks for cardiac morbidity and second cancers.
Because proton therapy may have some disadvantages, identifying the patients and the circumstances that may beneﬁt
the most from proton therapy is important. We present
modern guidelines to identify adult lymphoma patients who
may derive the greatest beneﬁt from proton therapy, along
with an analysis of the advantages and disadvantages of
proton treatment. (Blood. 2018;132(16):1635-1646)

Introduction

The guidelines presented here include an overview of proton
therapy for adult lymphomas involving the mediastinum, an indepth discussion of best practices along with examples of cases
in which protons offer an advantage, and reference to areas in
which further research is required. Although proton therapy is
useful for treating other anatomic locations, we focus on the
mediastinal location, because of the abundant data available.
Table 1 lists helpful deﬁnitions of technical terms used in the
article.

Reducing treatment-related toxic effects among survivors of
Hodgkin and non-Hodgkin lymphomas has been the cornerstone of recent advances in the treatment of hematologic
malignancies. Long-term follow-up studies of patients with
hematologic malignancies have produced strong and reliable
evidence that the beneﬁts from ionizing radiation may be
tempered by increased mortality and morbidity, particularly from
secondary malignancies and cardiac complications.1 These
ﬁndings fueled an immense effort to ﬁnd ways to minimize
collateral damage from radiation to adjacent thoracic organs at
risk (OARs). Some of those ways included 3-dimensional (3D)
conformal radiotherapy and intensity-modulated radiotherapy
(IMRT).2-5 Proton therapy, with its unique characteristics of lower
entrance dose, high-dose peak, and precipitous fall-off near
the end of beam range, presents another opportunity for more
conformal dose distribution and better OAR sparing.1,6,7
The guidelines represent a set of consensus recommendations
by expert radiation oncologists and physicists from different international academic centers. Best practice recommendations,
including potential beneﬁts or harms, were based on an extensive
review of the published literature. Every recommendation included
was reached by consensus of more than 80% of the authors in the
document; the article provides a reasoning for the recommendations, as well as an extensive explanation for recommendations
that were a matter of much debate among the authors.

© 2018 by The American Society of Hematology

Consensus recommendations
Lymphoma patients who can greatly beneﬁt from proton therapy
include (1) patients with mediastinal disease that spans below
the origin of the left main stem coronary artery and is anterior to,
posterior to, or on the left side of the heart; (2) young female
patients for whom proton therapy can reduce breast dose and
risk for secondary breast cancer; and (3) heavily pretreated
patients who are at higher risk for radiation-related toxicity to the
bone marrow, heart, and lungs.
When using proton therapy, treating physicians should (1) demonstrate by calculation that it provides greater beneﬁt to the
patient compared with optimally planned photon therapy;
(2) document the medical necessity of proton therapy, including
consideration of issues for long-term survivors and the risks
for radiogenic late effects; (3) understand the complexities of
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lymphoma proton planning, including the need to manage
uncertainties, and the evolving nature of the technology with
the development of pencil beam scanning, in-room volumetric
imaging, and robustness optimization; and (4) use deep inspiration breath hold (DIBH) when it further minimizes doses
to the OARs, with an understanding of the increased complexity of using DIBH with proton therapy compared with photon
therapy.

Table 1. Deﬁnitions
Term

Volume that contains the visible
extent of the tumor that can be
identiﬁable to contour and target
using a CT scan

Clinical tumor volume (CTV)

Volume that contains a suspected
microscopic disease; this could be
around the gross tumor or at the
original site after achieving
complete remission to
chemotherapy

Planning target volume

Volume that contains GTV and CTV;
in addition, it accounts for all
uncertainties like internal organ
movement and daily patient’s
setup errors

3D planning radiation therapy

Forward planning, deﬁne anatomy
on a CT scan, identify the target,
and create a radiation beam
arrangement to best encompass
the target; generate the radiation
dose that the operator judges
acceptable

Because the magnitude of dosimetric beneﬁt varies signiﬁcantly depending on the speciﬁc case, each case must be
considered individually, and the potential beneﬁt from proton
use should be weighed against the availability of the treatment
(need to travel), out-of-pocket costs if insurance coverage is
denied, resources required in terms of medical and physics
staff, and the potential uncertainties associated with proton
therapy.

IMRT

The operator feeds the planning
system the desired dose to the
target and organs at risk upfront
and what the end result dose
distribution should look like, then
the software will invert the
problem and let the computer
through a mathematical iteration
search for the best and optimized
solution; the software will keep
trying until the operator judges
the plan as acceptable

Linear energy transfer (LET)

Total amount of energy deposited
per unit distance in biological
materials by ionizing radiation

Radiobiological equivalent

Radiation relative biological
effectiveness depending on LET,
type of radiation particle, total
dose, and dose fractionation

Proton active scanning

Proton beam delivery using a pencil
beam that is precisely steered
through the treatment volume,
using a magnet in the beam line;
the dose is then deposited layer
by layer, allowing for a good
conformation

Proton passive scattering

Spatially uniform dose distribution
achieved by shaping the beam
through a set of devices at the
beam path

Intensity modulated proton
therapy

Further shapes the active scanning
to the distal tumor for irregularly
shaped tumors

Properties of the proton beam
Protons are charged particles that deposit radiation through
linear energy transfer (LET), losing little energy when entering
tissue and depositing most when slowing down just before
stopping, resulting in the Bragg peak effect.25 Because the
position of the peak strongly depends on the tissue density
along the beam path, proton therapy suffers from range uncertainties that clinicians need to understand to best use this
technology.

Proton therapy uncertainties and ways to
mitigate them
Some of the challenges associated with proton therapy are the
uncertainties arising from the beam-penetration range in tissues and the change in magnitude of biological effects along
the proton beam path. Uncertainties in calculating the range
of proton penetration in tissue have 2 major potential sources:
(1) range errors caused by changes in tissue density from errors
in setup (patient positioning), organ motion (eg, respiratory or
cardiac related), or anatomic changes (eg, tissue deformation
and tumor shrinkage), which collectively cause variations in
beam path and range that could cause inconsistencies between the planned and delivered treatments, and (2) the input
data used to plan the beam range (ie, conversion of computed
tomography [CT] number to proton linear stopping power). The
other major source of uncertainties is the change in magnitude
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of biological effect (described in terms of relative biological
effectiveness [RBE]) of protons along the beam path, which
affects targets and normal tissues.
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Gross tumor volume (GTV)

Diﬀerent techniques in delivering
proton therapy
Several dosimetric studies comparing proton with photon
plans8-21 have been conducted in an effort to establish the
beneﬁt and indications for the use of proton therapy in lymphoma, with the vast majority focusing on mediastinal involvement. They showed that there is an individualized and
potential beneﬁt in patients with dose reduction to the heart,
lungs, and breasts with proton therapy compared with 3D
conformal radiotherapy or IMRT.1 Additionally, the lack of
marginal relapses that are feared when using a highly conformal therapy like proton treatment has made it an appealing
treatment.22-24
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Figure 1. Robustness analysis based on DVHs showing multiple scenarios representative of different uncertainties and their resulting effect on the dose distribution
for a speciﬁc organ at risk or target.

Range uncertainties due to density variations
One potentially large source of range uncertainty is introduced by
patient anatomic variations. Speciﬁcally, the current standard of
care uses volumetric images as a basis to create a radiation
treatment plan for use days or even weeks later. At the time
of treatment, the delivered dose distribution will deviate from
the planned distribution due to changes in position or size of the
patient and tumor. These changes are not that important with
regard to photon therapy, but they can have a profound impact on
proton therapy dose distribution in the axial and lateral directions
of the beam. Of these, the axial deviations are synonymous with
range uncertainties; if the linear stopping power (closely related to
the mass density) of any voxel in the patient changes (relative to its
value used for treatment planning), then the range of all protons
passing through that voxel will also change.26

A wide variety of strategies have been developed to deal with
dosimetric uncertainties associated with anatomical changes.27,28
Robust optimization tools now allow users to include range
uncertainties, setup errors, and physiological motion by incorporating ﬁndings from multiple CT scans (such as 4-dimensional
[4D] CT) in the plan optimization and dose-calculation processes.
The effectiveness of these tools can be evaluated with robustness analysis, which involves calculating dose distributions
for various error scenarios. Families of dose-volume histograms
(DVHs) of clinical target volumes (CTVs) and OARs for several
uncertainties scenarios (ie, shifts along the x, y, and z directions
and the associated range uncertainties) are reviewed before
treatment delivery to ensure the acceptability of the plan.
Typically, the “worst-case” DVH of the band is used for evaluation (Figure 1).29,30

Table 2. Guide to acceptable dose, volume, and ﬁeld considerations
Ideal

Optimize
technique

Optimize ﬁeld (consider
ﬁeld reduction)

Unacceptable

Avoid maximum
dose landing in

Heart: left ventricle,
coronary arteries, valves39-41

Mean , 5 Gy

Mean, 5-15 Gy

Mean . 15 Gy

Mean . 30 Gy

Coronary vessels

Breast (age dependent)*

Mean , 4 Gy

Mean, 4-15 Gy

Mean . 15 Gy

Mean . 30 Gy

Glandular tissue

V5 , 55%

V5, 55-60%

—

V5 . 60%

V20 , 30%

Mean, 10-13.5 Gy

Structures

Lung38

Mean . 13.5 Gy

Mean , 10 Gy
Thyroid62

V25 , 62.5%

V25 , 62.5%

Whole thyroid

*The importance of adhering to breast-dose restrictions is inversely related to patient age.
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Figure 2. Three scenarios of the relation between mediastinal disease and the heart. (A) Showing how to use the takeoff of the left main stem coronary artery (outlined in
pink) to determine the upper and lower mediastinal locations. (B) Scenario 1: coronal CT images of a 28-year-old man with primary mediastinal lymphoma before (i) and after
(ii) 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP) chemotherapy presenting for consolidation with radiation. (Biii) Axial, coronal, and
sagittal views of an IMRT plan (upper panels) and a proton plan (lower panels). (Biv) Corresponding mean doses to critical structures using IMRT vs protons. (C) Scenario 2: coronal
CT images of a 25-year-old man with Hodgkin lymphoma before (i) and after (ii) 4 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy presenting
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In addition to dose perturbations in the periphery of a proton
ﬁeld, interference between the dynamic pencil beam with
motion of the target and other surrounding anatomy results in
local dose heterogeneities within the target. This interplay between respiration-induced anatomical motion and spot scanning
can lead to “hot” and “cold” regions of dose within the target
volume. Margins cannot compensate for the interplay effect,
but other solutions, including one or more of the following, can
help: spot repainting, increasing spot size, gating, or motionreduction techniques.8 Some 4D robust optimization algorithms
are available that can take into account density variations, but
the timing information required for interplay calculation is not
included in these algorithms.

This source of uncertainty results from conversion of Hounsﬁeld
units obtained from CT scans to tissue relative proton stopping
powers, proton beam reproducibility, uncertainties in water
measurement during beam commissioning, and errors in range
compensator fabrication.31 Although the magnitude of these
types of uncertainties is speciﬁc to each proton system (including
the delivery, imaging, and calculation components), individual
institutions can use “margin recipes” to ensure target coverage.
Such recipes are commonly based on the formulation introduced
by Moyers et al32: distal margin 5 a % of depth 1 b mm, where
a is related to uncertainties in dose calculation, and b is related
to errors independent of the dose calculation.

Uncertainties in RBE
In current clinical practice, the RBE of protons compared with
high-energy photons is assumed to be a constant value of 1.1. In
reality, the RBE is variable and is a complex function of several
quantities, including LET from the protons to the local medium,
dose per fraction, tissue and cell type, oxygenation, biological or
clinical end points, and other factors.33 Estimates of the effects of
these factors on RBE are available from in vitro studies, but in
vivo data in humans are still lacking.26 Nevertheless, the available
data suggest that proton RBE can increase at the Bragg peak,
perhaps more rapidly and nonlinearly at the distal edge. Because LET increases as the proton energy decreases with depth,
leading to elevated LET and associated RBE values at the end of
proton range, this raises concerns when the distal end of a
treatment ﬁeld is directed toward sensitive OARs. There is
controversy about the extent of the region over which the RBE
deviates from 1.1, and it might be .1.1. It is accepted that the
higher the energy and range straggling, the more range mixing
we see, explaining the variability in the dose at the end of the
Bragg peak.34,35 On the other hand, this deviation is believed
by others investigators to be small (a few millimeters around the
Bragg peak). Because RBE-based or even LET-based planning
is not commercially available, empirical methods to spare
structures from increases in RBE are used, including reduced
physical dose to the OAR at the distal edge of the beam, use of
multiple ﬁelds to spatially dilute the effect, range feathering
of the same ﬁeld, irradiating past the sensitive structures, or

Clinical presentations and applications of
proton beam therapy
Patients presenting with mediastinal disease, especially young
women, pose a treatment challenge in which proton therapy can
be very useful. This section addresses the general goals and
challenges in speciﬁc clinical situations.
Regardless of the type of radiation to be used, the basic rules in
clinically evaluating a radiation treatment plan are achievement
of the following: (1) cover the planning target volume (PTV) with
$95% of the dose; (2) minimize the dose to heart substructures,
including coronary arteries, left ventricle, and valves,36 as much
as reasonably possible; (3) minimize radiation to the breasts, with
high priority assigned to avoiding irradiation of large volumes of
the breasts in young women (,35 years old)37; and (4) minimize
dose to the lungs, including V5, V20, V30, and mean dose.38
Table 2 summarizes these points and can be useful as a guide for
fulﬁlling these requirements.38-41
It should be kept in mind that current clinical treatment-planning
systems lack a few key capabilities needed to create, optimize, or
evaluate candidate treatment plans. Speciﬁcally, stray radiation
exposure is typically underestimated beyond a few centimeters
outside the treatment ﬁeld, precluding routine risk projections
based on radiation exposure.42 Similarly, their risk-modeling
capabilities are limited, if they are present at all.43,44

Consideration of heart dose
The relation of disease to OARs determines the situations in
which proton therapy is most beneﬁcial. Speciﬁcally, with regard
to disease in the heart and its substructures, published ﬁndings
suggest that mean heart doses . 15 Gy are associated with
increased risk for cardiac morbidity.39 Mean heart dose is a rough
estimate used quite often45; mechanistically, however, ischemic
heart disease likely depends on mean heart dose, as well as on
the maximum dose to the heart substructures,46,47 especially with
regard to atherosclerosis of the coronary vessels. Consequently,
one must remain mindful of the high-dose volume, especially
with regard to potential RBE uncertainty for beams that end
within a few millimeters of the coronary vessels.21
For the purposes of this article, proton and photon plans in all of
the illustrations shown use DIBH, inclined board for females to
further avoid the breasts and, for IMRT, a butterﬂy technique.48-51
Scenario 1: mediastinal target is completely above the heart
with no axillary involvement The take-off of the left main stem
coronary artery is used to deﬁne whether the target is above
or below the heart (Figure 2A). In this example (Figure 2B), the
exposure of the heart is quite comparable, regardless of which
technique is used. Differences in DVHs, as well as the mean dose
to other structures, are similar to the proton and IMRT plans.

Figure 2 (continued) for consolidation with radiation. (Ciii) Axial, coronal, and sagittal views of an IMRT plan (upper panels) and a proton plan (lower panels). (Civ) Corresponding
mean doses to critical structures using IMRT vs protons. (D) Scenario 3: coronal CT images of a 30-year-old man with recurrent Hodgkin lymphoma as shown in the coronal images of a
PET/CT scan (i-ii) presenting for deﬁnitive radiation. (Diii) Axial, coronal, and sagittal views of an IMRT plan (upper panels) and a proton plan (lower panels). (Div) Corresponding mean
doses to critical structures using IMRT vs protons.
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Discrepancies between calculated and actual
proton ranges in tissue

allowing respiratory/cardiac motion to feather out the dose for
moving OARs.

Scenario 2: target spans the right side of the heart For the
targets on the right side of the heart, IMRT often provide
comparable doses to the heart and other structures as proton
therapy. Notably, however, even when proton plans give
a dosimetric advantage over IMRT plans, the magnitude of
advantage could vary between cases, and it needs to be judged
individually. For example, for the patient shown in Figure 2C,
the mean doses to critical structures from proton therapy are
sufﬁciently lower than those from IMRT to suggest that proton
therapy may be preferred because of the large volume spanning
the right side of the heart. This example illustrates the need for
careful consideration of individual cases before deciding on
treatment.

Consideration for axillary involvement
Proton therapy can signiﬁcantly reduce the radiation dose to the
breasts by speciﬁcally using ﬁelds that enter posteriorly and stop
short of exiting through the breast. Alternatively, if protons cannot
be used, other methods of displacing the breast can be used
instead, such as using an inclined board or physically moving the
breast out the beam path. Figure 3A shows how using proton
therapy can spare the breast in a case with axillary involvement.

Consideration of breast dose
The long-term risk for developing breast cancer is related to
exposure to high and low radiation doses.37,52 Especially when
treating young patients, efforts must be directed to keeping the
radiation dose to the breast tissue as low as possible. In most
cases involving mediastinal disease, the axilla is uninvolved, and
the radiation dose to the breast with IMRT or proton therapy will
be small. Although IMRT leads to greater volumes of breast
tissue receiving low-dose radiation, in some cases proton
therapy can lead to greater volumes of breast tissue receiving
high-dose radiation. It is unknown whether it is more important
to minimize the low-dose portion vs the high-dose portion;
subsequently, mean breast dose continues to be the best factor
for evaluating different plans. However, at this time, a high dose
to a small volume is generally favored over a low dose to a large
volume based on ﬁndings suggesting that doses as low 4 Gy37
can be associated with a risk for long-term second malignancies,
especially in patients younger than 24 years of age. Although
the dose calculation by Travis et al37 refers to a point dose (not
a mean), we still recommend erring on the side of caution in
an attempt to keep the mean breast dose # 4 Gy.
When hilar disease needs to be covered, the dose to the breasts
can increase, and avoiding the breasts becomes difﬁcult with
either modality (proton or photon). The choice of treatment
modality for such cases must consider the doses received by
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Consideration of lung dose
With the advent of CT-based planning for mediastinal lymphoma,
the dose to the lungs can now be correlated with the risk for
pneumonitis. Restrictions on lung dose are encouraged to be V5 ,
55%, mean lung dose , 13.5 Gy, and V30 , 20%. These values are
more attainable with the use of DIBH.38 Although a mean lung
dose of 13.5 Gy has been associated with a lower risk for pneumonitis, it is advisable to aim for a lower dose, which is quite often
attainable when strict constraints are used. For example, when
IMRT is used, it is important to limit the beams to some variation of
anteroposterior beams, avoiding lateral beams. If avoiding the lung
is the primary objective for a given patient, especially if that patient
has received pulmonary-toxic chemotherapy (eg, bleomycin,
busulfan, gemcitabine, brentuximab), proton therapy may better
spare the lungs by reducing the low-dose bath seen with photons
(Figure 3C).

Current techniques for delivering proton
beam therapy
Passive scattering proton therapy
Passive scattering proton therapy (PSPT) is the least complex
proton-delivery technique; the beam is broadened laterally by
placing scattering material in the beam path. Range modulator
wheels or ridge ﬁlters are used to create the spread out Bragg
peak, a region of ﬂat dose distribution meant to cover the target
laterally and longitudinally. The entire spread out Bragg peak is
delivered nearly instantaneously (,0.1 second), so there is no
interplay between the proton beam and physiological motion
during delivery, making PSPT the most robust form of proton
delivery.53

Challenges in planning PSPT
Conforming to target heterogeneity (eg, contiguous subvolumes
of varying size, shape, and depth) is challenging; PSPT beams can
only conform to 1 side of the target, either proximally or distally.
Also, large targets often necessitate matching ﬁelds because of
the limited maximum size of the scattered beams. Dose inhomogeneity produced by matching beams is alleviated by
match-line changes, which increase the treatment complexity.
Motion management in PSPT requires the use of accurate
motion analysis, adequate margin determination, and motionreduction techniques. For free-breathing treatments, 4D CT is
used to evaluate target displacement perpendicularly to the
beam and to expand the width of the beam. Along the beam,
motion is evaluated by the maximum difference in waterequivalent depth from the patient surface to the distal edge
of the target for each beam, based on the density changes of the
4D CT, and is accounted for by compensator smearing. DIBH
reduces the target motion and accounts for the tissue interfaces.
The plan target is the CTV; when the treatment area is affected
by breathing motion, the plan target is the internal target volume

DABAJA et al
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Scenario 3: target is on both sides of the heart Disease that
spans signiﬁcantly in front of the heart anteriorly, posteriorly, or
to the left side poses a particular challenge for IMRT; therefore,
proton therapy may be the superior plan. Notably, toxicity to the
heart and lungs is not eliminated by using proton therapy; rather,
the dose to the heart may be lower than IMRT. Thus, for cases
like in Figure 2D, clinicians should carefully weigh the therapeutic beneﬁt against the long-term risks for radiation-induced
treatment toxicities before deciding on which technique should
be used. Indeed, in this case, proton therapy can signiﬁcantly
avoid the heart and should be sought in an attempt to reduce the
dose to the heart substructures.

other critical structures, such as the heart and lungs, especially in
previously and heavily treated patients. However, in considering
how to best limit the volumes exposed to radiation, avoiding
“low-dose baths” is equally important (ie, irradiation of large
volumes with low doses), regardless of which modality is used
(Figure 3B).

Figure 3. Axillary involvement at presentation. (A) Axial,
coronal, and sagittal views of a proton plan (left) and an
IMRT plan (right) for a patient presenting with axillary involvement. Use of proton therapy in this case spares the
left breast. (B) Regardless of which treatment modality is
chosen, IMRT (left panel) and proton (right panel), limiting
the volume exposed to radiation should include attention
to avoiding a low-dose bath. (C) Limiting lung dose. If
avoiding the lung is the primary objective in a given patient, especially if the patient has received pulmonary toxic
chemotherapy (eg, any combination of bleomycin, busulfan, gemcitabine, brentuximab, etc.), proton therapy may
better spare the lungs by reducing the low-dose bath seen
with photons.

A

IMRT/ dose

Proton/ dose

Heart

14.6 Gy (mean)

9.9 Gy (mean)

Breast

6.7 Gy (mean)

2.6 Gy (mean)

Lungs

9.6 Gy (mean)

8.9 Gy (mean)

LAD

24.5 Gy (mean)

21.1 Gy (mean)

LAD

32.9 Gy (max)

34.8 Gy (max)

Left ventricle

14.3 Gy (mean)

7.8 Gy (mean)

Body

7.2 Gy (integral)

3.7 Gy (integral)

Esophagus

18.5 Gy (mean)

15.1 Gy (mean)
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(ITV), which encompasses the motion of the CTV depicted on
4D CT scans. Alternately, if treatment is to be given with DIBH, an
ITV can be derived from the positions of the CTV reproduced
from multiple DIBH scans. For lateral beam shaping, margin
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expansion to form the PTV accounts for setup uncertainty, and
interfractional variability in anatomy is applied to the CTV/ITV.
Patient-speciﬁc beam collimators conform the dose laterally to the
PTV, with a margin for penumbra. Depending on the target depth
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Figure 4. An example of an approach using 2 anterior ﬁelds with proton therapy, which can better spare the heart and esophagus (right) compared with an
anterior/posterior approach (left).

and adjacent tissue, these margins vary from 5 to 10 mm. Range
compensators are designed for each beam to conform the dose
distally to the CTV/ITV. Range compensator smearing within a
radius appropriate for setup tolerances and tissue motion is applied
to account for proton range changes caused by density changes in
the beam path. In addition, along each beam, distal and proximal
margins are set to the CTV/ITV to compensate for proton range
uncertainties, as described under “Range uncertainties due to
density variations.” Multiple beams (compared with 1 beam) can be
used to increase dose conformality and reduce dose uncertainties
by spreading the beams in various directions. The preference is to
use anterior or posterior ﬁelds, rather than both, because of the
need to avoid unnecessary beam through the heart (Figure 4).

Pencil beam scanning proton therapy
Compared with PSPT, active-mode pencil beam scanning proton therapy (PBSPT) offers the potential for better conformality
and OAR sparing. 54 Because treatment involves delivery of
individually controlled spots, inhomogeneous doses can be

created deliberately. PBSPT has the potential to deliver lower
doses to OARs by its ability to conform the dose proximal to the
target, by its improved conformality distal to the target, and by
reducing the formation of secondary neutrons produced in the
treatment apparatus.55,56 However, lateral penumbral widths of
some uncollimated scanned beams may be larger than those
achieved with collimated passively scattered proton beams. When
each scanned treatment ﬁeld is used to treat the entirety of the
target, the techniques is termed “single-ﬁeld uniform dose.”
Conformality can be improved further with the use of an intensitymodulated approach (ie, intensity-modulated proton therapy), in
which each beam is used to treat only part of the target volume;
this technique is analogous to step-and-shoot IMRT. Compared
with PSPT beams, PBSPT ﬁelds are larger, so larger targets can
be treated without matched ﬁelds. However, when matches are
required, PBSPT allows “gradient matching,”57,58 which obviates
the need for match-line changes. Gradient matching can be
used for opposing beams targeting different regions of complicated target volumes, as described below.

Figure 5. Plans for PBSPT with a single-ﬁeld uniform
dose and a gradient match, with anterior and posterior beams used to treat disease that involves the
bilateral upper neck and the mediastinum (disease
anterior to the right heart).
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Anterior
posterior

Figure 6. Scans for a young woman in whom the
target included mediastinal, left parasternal, and left
axillary regions. One anterior ﬁeld was used for the
mediastinum, and a separate posterior ﬁeld was used for
the axillary region.

lungs (Figure 6). For upper neck targets, lateral or posterior ﬁelds
can avoid the oral cavity/salivary structures. For axillary targets, a
posterior ﬁeld can help to spare breast tissue. Although these
various ﬁeld arrangements can be used in PSPT, gradient
matching is simpler in PBSPT when the ﬁelds overlap or oppose,
obviating the need for feathering.

Motion management Use of PBSPT requires close attention to
evaluation of intrafractional movement, which is usually connected with the breathing cycle. A free-breathing technique can
be safely used when speciﬁc conditions are fulﬁlled.54 Use of
PBSPT with free breathing requires 4D CT scanning to evaluate
the motion of internal structures during the breathing cycle.
Robustness is improved by using a repainting strategy, which
reduces the potential for the interplay effect. For patients with
target motion than exceeds 5 mm over the breathing cycles,
alternate strategies can be used, such as DIBH, respiratory gating,
abdominal compression, or repositioning.

Veriﬁcation of patient position and dose distribution in PSPT or
PBSPT Proton-delivery systems are equipped with orthogonalkV imaging systems used for daily patient setup. Newer systems have cone beam CT capabilities. Although PSPT and
PBSPT plans can be made to account for setup errors and
breathing motion, dose veriﬁcation is recommended. The previously described margins do not protect against unpredictable
changes that occur during the course of treatment, such as lymphoma progression, pleural effusion, pneumonia, or weight loss. If
image-guided treatment setup is not based on 3D imaging, repeat veriﬁcation CT imaging and dose recalculation are recommended to verify the accuracy of the treatment. Adaptive planning
is advised (eg, in refractory-relapsed disease) when the target
coverage is not maintained or the OAR dose constraints are
violated during the course of treatment

With regard to patient positioning, it is essential to ensure reproducibility between fractions. Compared with PSPT, PBSPT
requires even more stringent reproducibility because of its greater
sensitivity to density changes in the beam path.
With regard to ﬁeld arrangements, the PBSPT technique for
an anterior upper mediastinal and lower neck target usually requires 1 (repainted) or 2 anterior ﬁelds. For more complex target
volumes, targets can be divided into 2 or more parts (eg, neck
CTV, mediastinal CTV, and axillary CTV), and a multiﬁeld plan
can be used (Figure 5). For cases that involve lower (posterior)
and upper (anterior) mediastinal targets, a combination of posterior and anterior ﬁelds can maximally spare the heart and

Thinner Mediastinum with DIBH

ILROG PROTON GUIDELINES

Treatment planning
Target delineation and margins
Target deﬁnition follows the modern deﬁnition of involved-sites
radiation previously published by the International Lymphoma
Radiation Oncology Group (ILROG).3 The CTV/ITV and normal
structures are delineated in the same way for proton therapy as
for photon therapy. Because of uncertainties in proton range, the

Wider Mediastinum with free breathing

Figure 7. Use of DIBH can help to manage some of the
uncertainties associated with the use of proton therapy.
Compared with free breathing (right panel), DIBH expands
the lungs, moves the heart downward, and causes the
mediastinum to become thinner (left panel).
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Challenges of PBSPT Compared with PSPT, PBSPT is more
sensitive to density changes in the beam path; thus, motion
management is of prime importance. Whereas interfractional
changes and tumor shrinkage can require adaptive planning
when PSPT, the increased sensitivity to beam path variations
makes this even more important when PBSPT is used.

validity of the concept of PTV is questionable. In the current
practice of PSPT, margins to the CTV are assigned per beam,
and lateral margins are the same as for photons; however, distal
and proximal margins depend on the depth of the distal and
proximal edges of the target. This results in what is called the
“beam-speciﬁc PTV.” This practice is not applicable to intensitymodulated proton therapy, in which robust optimization is the
recommended solution.

Motion management

DIBH can be accomplished in several ways, such as by actively
blocking airﬂow, voluntary breath holding, or synchronization
(respiratory gating). Each of these methods has advantages and
limitations when used with proton therapy, particularly PBSPT,
which tends to have longer “beam-on” time than PSPT. Interfractional reproducibility of the diaphragm position during the
course of the radiation fraction should be evaluated.60,61 Regardless of the breath-hold technique used, on-board imaging
can be useful to verify and check the daily reproducibility of the
lung volume against that in the treatment-planning CT.

Each proton therapy center has different capacities and techniques, and no uniﬁed technique for proton radiotherapy for
patients with lymphoma has been widely adopted. Ultimately,
key tools and concepts should be applied, and a minimum requirement for competency should be acquired for those who
intend to use proton therapy.
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The use of proton therapy for lymphomas engaging the mediastinum is promising, and treatment techniques continue to
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